secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0002019410-25-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M
--------------------------------------------------------------------------------

- Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).
- Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.
- Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.
- Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.
- Molecular profiling services revenue grew 121.3% YoY to $207.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/0002019410-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/cai-20251105.htm
  HTML page:      https://secwatch.observer/filing/0002019410-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer